Sudeep Pharma Limited (SUDEEPPHRM) — Announcement

📢 Key Event
Sudeep Pharma announces FY26 results and European acquisition to drive specialty ingredients growth.

🔄 What Changed
PAT margin improved to 27.1% and revenue grew 16% YoY in FY26

🔮 What's Next
None

💡 Investor Takeaway
The acquisition and capacity expansions position Sudeep Pharma for sustained growth in high-demand specialty markets.

⚠️ Risks
None

Sudeep Pharma Limited reported FY26 revenue of ₹642.3 crores, up 16% YoY, with PAT rising to ₹174.3 crores (27.1% margin) and EPS at ₹12.79. The company strengthened its European footprint through an 85% acquisition of a vitamin and mineral blends business, targeting synergies in cross-selling and novel formulations. Strategic investments in battery materials and greenfield projects support growth in high-margin segments like infant nutrition and EV supply chains, backed by robust cash generation of ₹69.5 crores from operations.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUDEEPPHRM ✨ Ask AI About This